Teva Pharmaceuticals' efforts to cut costs by making its manufacturing more efficient have landed at a plant in the U.K. where the generics leader will cut dozens of jobs but add some new positions with more specialized skills.
Orlando-based Nephron Pharmaceuticals will cut another 250 positions in Florida as it transfers its manufacturing to a newer site in South Carolina.
Anyone who's examined Pfizer's job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. But this time? Things will be different, CEO Ian Read said of Pfizer's Allergan tie-up on Tuesday at the J.P. Morgan Healthcare Conference.
Perrigo, in an effort to hive off $175 million a year in costs, is laying off 6% of its workforce, among other steps.
As Lundbeck cuts staff and reshuffles R&D, one of its drug candidates has come out a winner.
The job cuts at Merck have been massive ever since its 2009 merger with Schering-Plough, 36,000 in 5 years. They have almost run their course, but manufacturing will make up most of what is left as it continues to shed manufacturing plants.
Healthcare was one of the strongest segments at German conglomerate Siemens last quarter, both in terms of sales growth and profitability. That could help insulate this business, comprised mostly of imaging and diagnostics, from an ongoing restructuring that aims to trim employees and costs from its worst performing businesses.
Now that it's teamed up with Novartis' consumer health unit to form an industry-leading joint venture, GlaxoSmithKline's OTC business is bigger than ever. But its payroll is about to get smaller, with 350 layoffs hitting the operation.
Zimmer will close its Carlsbad, CA, dental headquarters following its looming $13 billion merger with Biomet, resulting in an unspecified number of layoffs. The plant closure will occur in 12 months, say internal company emails sent to both companies' employees that were obtained by FierceMedicalDevices.
The big asset swap between GlaxoSmithKline and Novartis may have given each just what it wanted, but the deal continues to play out poorly for workers, with GSK planning to close its Pittsburgh office where it has about 275 employees working for its consumer health unit.